Anidulafungin(LY303366)
| Catalogue No. : |
C14801 |
| Product Name: |
Anidulafungin(LY303366) |
| Synonym: |
Ecalta; Eraxis;LY 303366 |
| Chemical Name: |
N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)- 6-[(1S,2R)-1,2-dihydroxy- 2-(4-hydroxyphenyl)ethyl]- 11,20,21,25-tetrahydroxy- 3,15-bis[(1R)-1-hydroxyethyl]- 26-methyl- 2,5,8,14,17,23-hexaoxo- 1,4,7,13,16,22-hexaazatricyclo [22.3.0.09,13] heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide;1-[(4R,5R)-4,5-dihydroxy-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-Echinocandin B |
| CAS No. : |
166663-25-8 |
| Structure : |
|
| Molecular Formula: |
C58H73N7O17 |
| Molecular Weight: |
1140.24 |
| Appearance: |
Almost yellow powder |
| Purity: |
Not less than 95.0%(w/w) in HPLC method |
| Usage: |
Anidulafungin is an anti-fungal drug. It has proven efficacy against oesophageal candidiasis, but its main utility will probably be in invasive Candida infection; It will probably also have application in treating invasive Aspergillus infection. It is a member of the class of anti-fungal drugs known as the echinocandins: Its mechanism of action is by inhibition of (1-3)β -D-glucan synthase, which is an important component of the fungal cell wall. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
